363 related articles for article (PubMed ID: 23839530)
1. Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.
Vogt W
Clin Pharmacokinet; 2014 Jan; 53(1):51-72. PubMed ID: 23839530
[TBL] [Abstract][Full Text] [Related]
2. Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery.
Mizuno T; Gist KM; Gao Z; Wempe MF; Alten J; Cooper DS; Goldstein SL; Vinks AA
Clin Pharmacokinet; 2019 Jun; 58(6):793-803. PubMed ID: 30607889
[TBL] [Abstract][Full Text] [Related]
3. Treatment for paediatric low cardiac output syndrome: results from the European EuLoCOS-Paed survey.
Vogt W; Läer S
Arch Dis Child; 2011 Dec; 96(12):1180-6. PubMed ID: 22034494
[TBL] [Abstract][Full Text] [Related]
4. Time-Varying Clearance in Milrinone Pharmacokinetics from Premature Neonates to Adolescents.
O'Hanlon CJ; Sumpter A; Anderson BJ; Hannam JA
Clin Pharmacokinet; 2024 May; 63(5):695-706. PubMed ID: 38613610
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease.
Burkhardt BE; Rücker G; Stiller B
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009515. PubMed ID: 25806562
[TBL] [Abstract][Full Text] [Related]
6. A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery.
Bailey JM; Hoffman TM; Wessel DL; Nelson DP; Atz AM; Chang AC; Kulik TJ; Spray TL; Akbary A; Miller RP; Wernovsky G
J Pharmacokinet Pharmacodyn; 2004 Feb; 31(1):43-59. PubMed ID: 15346851
[TBL] [Abstract][Full Text] [Related]
7. Prevention for pediatric low cardiac output syndrome: results from the European survey EuLoCOS-Paed.
Vogt W; Läer S
Paediatr Anaesth; 2011 Dec; 21(12):1176-84. PubMed ID: 21851475
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics and Dosing of Milrinone After Patent Ductus Arteriosus Ligation in Preterm Infants.
Hallik M; Ilmoja ML; Tasa T; Standing JF; Takkis K; Veigure R; Kipper K; Jalas T; Raidmäe M; Uibo K; Starkopf J; Metsvaht T
Pediatr Crit Care Med; 2019 Jul; 20(7):621-629. PubMed ID: 30664589
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study. Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics.
Hoffman TM; Wernovsky G; Atz AM; Bailey JM; Akbary A; Kocsis JF; Nelson DP; Chang AC; Kulik TJ; Spray TL; Wessel DL
Am Heart J; 2002 Jan; 143(1):15-21. PubMed ID: 11773907
[TBL] [Abstract][Full Text] [Related]
10. Drug use patterns for the prevention of paediatric low cardiac output syndrome in Europe.
Vogt W; Läer S
Intensive Care Med; 2011 Aug; 37(8):1390-1. PubMed ID: 21647715
[No Abstract] [Full Text] [Related]
11. Dosing of Milrinone in Preterm Neonates to Prevent Postligation Cardiac Syndrome: Simulation Study Suggests Need for Bolus Infusion.
Hallik M; Tasa T; Starkopf J; Metsvaht T
Neonatology; 2017; 111(1):8-11. PubMed ID: 27490706
[TBL] [Abstract][Full Text] [Related]
12. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.
Willmann S; Becker C; Burghaus R; Coboeken K; Edginton A; Lippert J; Siegmund HU; Thelen K; Mück W
Clin Pharmacokinet; 2014 Jan; 53(1):89-102. PubMed ID: 23912563
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
Edginton AN; Schmitt W; Willmann S
Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
[TBL] [Abstract][Full Text] [Related]
14. Prevention of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery: A Double-Blind Randomized Clinical Pilot Study Comparing Dobutamine and Milrinone.
Cavigelli-Brunner A; Hug MI; Dave H; Baenziger O; Buerki C; Bettex D; Cannizzaro V; Balmer C
Pediatr Crit Care Med; 2018 Jul; 19(7):619-625. PubMed ID: 29538053
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Hoffman TM; Wernovsky G; Atz AM; Kulik TJ; Nelson DP; Chang AC; Bailey JM; Akbary A; Kocsis JF; Kaczmarek R; Spray TL; Wessel DL
Circulation; 2003 Feb; 107(7):996-1002. PubMed ID: 12600913
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Evaluation of Milrinone Pharmacokinetics in Children With Kidney Injury.
Gist KM; Mizuno T; Goldstein SL; Vinks A
Ther Drug Monit; 2015 Dec; 37(6):792-6. PubMed ID: 25860636
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, hemodynamic and metabolic effects of epinephrine to prevent post-operative low cardiac output syndrome in children.
Oualha M; Urien S; Spreux-Varoquaux O; Bordessoule A; D'Agostino I; Pouard P; Tréluyer JM
Crit Care; 2014 Jan; 18(1):R23. PubMed ID: 24456639
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and dosing regimen design of milrinone in preterm infants.
Paradisis M; Jiang X; McLachlan AJ; Evans N; Kluckow M; Osborn D
Arch Dis Child Fetal Neonatal Ed; 2007 May; 92(3):F204-9. PubMed ID: 16690639
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial.
Wang A; Cui C; Fan Y; Zi J; Zhang J; Wang G; Wang F; Wang J; Tan Q
Crit Care; 2019 Dec; 23(1):428. PubMed ID: 31888711
[TBL] [Abstract][Full Text] [Related]
20. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.
Rasool MF; Khalil F; Läer S
Clin Pharmacokinet; 2015 Sep; 54(9):943-62. PubMed ID: 25773479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
